| Authors: |
Kum DB; Aligos Belgium BV, Leuven, Belgium.; Aligos Therapeutics Inc., South San Francisco, California, USA., Vanrusselt H; Aligos Belgium BV, Leuven, Belgium., Acosta Sanchez A; Novalix, Leuven, Belgium., Taverniti V; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France., Verrier ER; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France., Baumert TF; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France.; Hepato-digestive Division, IHU Strasbourg, Strasbourg University Hospitals, Strasbourg, France., Liu C; Aligos Therapeutics Inc., South San Francisco, California, USA., Deval J; Aligos Therapeutics Inc., South San Francisco, California, USA., Corthout N; VIB Bio-imaging Core, Leuven, Belgium., Munck S; VIB Bio-imaging Core, Leuven, Belgium., Beigelman L; Aligos Therapeutics Inc., South San Francisco, California, USA., Blatt LM; Aligos Therapeutics Inc., South San Francisco, California, USA., Symons JA; Aligos Therapeutics Inc., South San Francisco, California, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Jekle A; Aligos Therapeutics Inc., South San Francisco, California, USA., Vendeville S; Aligos Belgium BV, Leuven, Belgium., Debing Y; Aligos Belgium BV, Leuven, Belgium. |